FIELD: medicine; pharmaceuticals.
SUBSTANCE: pharmaceutical composition in the form of pellets, characterised by that it has a coating containing copolymer of methacrylic acid and ethyl acrylate (1:1) and triethyl citrate, applied on a core consisting of the internal phase containing quetiapine fumarate or quetiapine, copolymer of methacrylic acid and ethyl acrylate (1:1), lactose, anhydrous crystalline maltose, and external phase containing talc and magnesium stearate. Method involves double wet granulation, drying, addition of lubricating and sliding substances, pressing and application of coating on the ready tablet.
EFFECT: tablet atypical antipsychotic agents are effective and stable during storage.
2 cl, 7 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| LAXATIVE SOLID DOSAGE FORM AND METHOD FOR PREPARING THEREOF (VERSIONS) | 2009 |
|
RU2401106C1 |
| MODIFIED RELEASE DOSAGE FORM OF TRIMETAZIDINE DIHYDROCHLORIDE | 2009 |
|
RU2412706C1 |
| PHARMACOLOGICAL COMPOSITION WITH SWELLING COATING | 2004 |
|
RU2375048C2 |
| COATED COMPOUND CONTAINING PHARMACEUTICAL AGENT | 2004 |
|
RU2372893C2 |
| PROLONGED-RELEASE PHARMACEUTICAL COMPOSITION OF ENTACAPONE OR ITS SALTS | 2009 |
|
RU2540465C2 |
| PHARMACEUTICAL COMPOSITION IN FORM OF SINGLE ORAL DOSE CONTAINING LEVODOPA, CARBIDOPA AND ENTACAPONE, OR SALTS THEREOF | 2009 |
|
RU2519159C2 |
| MESALAZINE TABLET WITH IMPROVED SOLUBILITY | 2011 |
|
RU2610435C2 |
| THE PHARMACEUTICAL COMPOSITIONS CONTAINING pH - DEPENDENT MEDICAL PRODUCT, THE pH MODIFIER AND THE SLOWING DOWN AGENT | 2006 |
|
RU2442574C2 |
| METHOD FOR PREPARING SOLID, ORAL PHARMACEUTICAL FORMULATION | 2009 |
|
RU2493850C2 |
| PROLONGED ACTION PHARMACEUTICAL COMPOSITION BASED ON 5-ETHOXY-2-[2-(MORPHOLINO)-ETHYLTHIO]BENZIMIDAZOLE DIHYDROCHLORIDE AND/OR BASE (APHOBAZOLUM) | 2017 |
|
RU2694837C2 |
